Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
SSE:603707.SS
11.31 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,923.586 | 3,931.387 | 3,712.72 | 3,686.693 | 2,914.881 | 2,469.669 | 1,700.331 | 1,112.726 | 581.913 | 468.728 | 416.121 | 499.817 |
| Cost of Revenue
| 2,228.37 | 2,028.721 | 1,767.998 | 1,596.122 | 1,196.265 | 1,204.33 | 859.24 | 596.684 | 337.007 | 340.088 | 326.229 | 367.892 |
| Gross Profit
| 1,695.216 | 1,902.666 | 1,944.723 | 2,090.571 | 1,718.616 | 1,265.339 | 841.091 | 516.042 | 244.906 | 128.64 | 89.892 | 131.925 |
| Gross Profit Ratio
| 0.432 | 0.484 | 0.524 | 0.567 | 0.59 | 0.512 | 0.495 | 0.464 | 0.421 | 0.274 | 0.216 | 0.264 |
| Reseach & Development Expenses
| 329.922 | 372.294 | 263.662 | 220.955 | 187.532 | 166.349 | 101.182 | 77.185 | 49.048 | 27.883 | 24.171 | 0 |
| General & Administrative Expenses
| 58.858 | 44.389 | 63.119 | 41.006 | 36.96 | 17.228 | 12.035 | 13.943 | 8.821 | 6.321 | 4.532 | 50.861 |
| Selling & Marketing Expenses
| 280.004 | 420.572 | 451.717 | 483.816 | 446.195 | 358.276 | 247.683 | 46.969 | 9.955 | 5.023 | 2.967 | 2.075 |
| SG&A
| 338.863 | 464.961 | 514.836 | 524.822 | 483.155 | 375.505 | 259.719 | 60.911 | 18.776 | 11.344 | 7.499 | 52.935 |
| Other Expenses
| 32.103 | 18.128 | 133.553 | 103.221 | 71.71 | 47.762 | 7.288 | 3.762 | 112.7 | 2.928 | 2.681 | 1.631 |
| Operating Expenses
| 700.887 | 2,197.375 | 912.05 | 848.998 | 742.397 | 589.615 | 390.292 | 173.75 | 100.21 | 58.718 | 44.374 | 54.497 |
| Operating Income
| 994.328 | -331.908 | 1,173.552 | 1,181.933 | 876.982 | 667.641 | 460.431 | 352.442 | 161.076 | 98.594 | 59.276 | 79.742 |
| Operating Income Ratio
| 0.253 | -0.084 | 0.316 | 0.321 | 0.301 | 0.27 | 0.271 | 0.317 | 0.277 | 0.21 | 0.142 | 0.16 |
| Total Other Income Expenses Net
| -2.295 | 37.15 | 11.817 | 17.934 | 37.65 | 12.724 | 7.288 | 3.762 | 112.531 | 2.928 | 1.731 | 1.63 |
| Income Before Tax
| 992.034 | -294.759 | 1,185.369 | 1,203.754 | 914.632 | 680.366 | 467.719 | 356.204 | 273.607 | 101.522 | 61.007 | 81.372 |
| Income Before Tax Ratio
| 0.253 | -0.075 | 0.319 | 0.327 | 0.314 | 0.275 | 0.275 | 0.32 | 0.47 | 0.217 | 0.147 | 0.163 |
| Income Tax Expense
| 165.935 | -105.312 | 98.85 | 139.838 | 117.977 | 74.124 | 43.17 | 41.982 | 16.367 | 13.968 | 10.547 | 11.059 |
| Net Income
| 826.145 | -189.446 | 1,090.833 | 1,059.293 | 806.122 | 604.962 | 424.549 | 314.222 | 257.24 | 87.553 | 50.49 | 70.316 |
| Net Income Ratio
| 0.211 | -0.048 | 0.294 | 0.287 | 0.277 | 0.245 | 0.25 | 0.282 | 0.442 | 0.187 | 0.121 | 0.141 |
| EPS
| 0.51 | -0.12 | 0.68 | 0.67 | 0.51 | 0.38 | 0.35 | 0.21 | 0.19 | 0.084 | 0.049 | 0.07 |
| EPS Diluted
| 0.5 | -0.12 | 0.68 | 0.67 | 0.51 | 0.38 | 0.35 | 0.21 | 0.19 | 0.084 | 0.049 | 0.07 |
| EBITDA
| 1,241.519 | -57.844 | 1,363.092 | 1,387.43 | 1,057.724 | 745.872 | 516.752 | 401.632 | 313.348 | 125.441 | 79.302 | 86.321 |
| EBITDA Ratio
| 0.316 | -0.015 | 0.367 | 0.376 | 0.363 | 0.302 | 0.304 | 0.361 | 0.538 | 0.268 | 0.191 | 0.173 |